JHOP Articles

Skip to main content

FDA Updates

Jaypirca, a New BTK Inhibitor, Received FDA Accelerated Approval for Relapsed or Refractory Mantle-Cell Lymphoma

FDA Updates

FDA Approved Lunsumio for Relapsed or Refractory Follicular Lymphoma

FDA Updates

Adstiladrin, First Adenoviral Vector–Based Gene Therapy, FDA Approved for High-Risk Non–Muscle Invasive Bladder Cancer

FDA Updates

Krazati Received Accelerated FDA Approval for NSCLC with KRAS G12C Mutation

FDA Updates

Keytruda Received FDA Approval for Adjuvant Treatment of Non–Small-Cell Lung Cancer

FDA Updates

Tukysa, in Combination with Trastuzumab, Now FDA Approved for HER2-Positive Unresectable or Metastatic Colorectal Cancer

FDA Updates

Brukinsa Now FDA Approved for Patients with CLL or SLL

FDA Updates

Tecentriq Now FDA Approved for Treatment of Alveolar Soft-Part Sarcoma

Multiple Myeloma

Teclistamab Showed Durable Responses in Heavily Pretreated Patients with Multiple Myeloma

GC012F, an Autologous BCMA and CD19 Dual-Targeting CAR T-Cell Therapy, as First-Line Treatment for Transplant-Eligible Patients with Newly Diagnosed High-Risk Multiple Myeloma

Page 38 of 196
Results 371 - 380 of 1953